NEW YORK, Sept. 18, 2025 The Gross Law Firm has officially reached out to shareholders of Replimune Group, Inc. (NASDAQ: REPL), encouraging those who experienced financial losses to join a class action lawsuit. This legal movement arises in light of the company’s recent undesirable performance in the financial markets, raising serious concerns about corporate governance and financial disclosures at Replimune. Context of the Urgent NoticeReplimune Group, Inc., a clinical-stage biotechnology company developing innovative immuno-oncology therapies, has shown promise in the biopharmaceutical sector. However, contrary to initial enthusiasm surrounding the company’s potential growth, shareholders are now co...
Replimune Group, Inc. Inducement Grants Overview Replimune Group, Inc. (NASDAQ: REPL), a biotechnology firm engaged in the development of innovative oncolytic immunotherapies, recently issued a press release regarding the grant of inducement equity awards to newly hired non-executive employees. This announcement, made on January 10, 2025, aligns with the Nasdaq Listing Rule 5635(c)(4), which outlines certain requirements for companies when granting equity awards.According to the company, these inducement grants have been offered as part of a strategic initiative to attract skilled talent to bolster their workforce. The decision to provide such awards underscores the firm s commitment to enhancing its capabil...
Replimune’s RP1 Shows Promise in Anti-PD1 Resistant Melanoma, Sets New Benchmarks Replimune Group Inc made a significant splash at the European Society for Medical Oncology (ESMO) Congress 2024, presenting the primary analysis data from their IGNYTE clinical trial involving RP1 in combination with nivolumab. The data unveils groundbreaking results, especially for melanoma patients who have previously failed anti-PD1 therapies. This article delves into the compelling findings from the IGNYTE trial and explores their potential ramifications for Replimune s financial health and positioning within the biotech industry. Key Findings from the IGNYTE TrialThe IGNYTE trial s primary analysis focused on RP1, an onc...
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual MeetingThe promising potential of RP1 monotherapy in treating skin cancers in recipients of solid organ and hematopoietic cell transplants was highlighted during the oral presentation of interim results from the ARTACUS clinical trial at the American Association of Cancer Research (AACR) 2024 Annual Meeting. The data unveiled a clear anti-tumor activity of RP1 monotherapy, showcasing an overall response rate of nearly 35 percent and a complete response rate of nearly...
Replimune Group Inc., a leading biotechnology company focused on developing innovative oncolytic immunotherapies, recently announced its initial primary analysis results from the CERPASS clinical trial in advanced cutaneous squamous cell carcinoma (cSCC) and presented new data from the IGNYTE clinical trial of RP1 in anti-PD1 failed melanoma and non-melanoma skin cancers. While the clinical trial results showed encouraging signs of progress, the company s financial report revealed some interesting findings as well. In the CERPASS clinical trial, Replimune evaluated the combination of RP1 with cemiplimab, a PD-1 inhibitor. The trial showcased clinically meaningful improvements in the complete re...
Sources:
Replimune Group Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Replimune Group Inc’s corporate clients.
For your research, we’ve provided 9 tables on Replimune Group Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
